Skip to content

Study · In vitro (cells) · 2000

2 results

Adenosine: A partial agonist of the growth hormone secretagogue receptor.

Smith RG, Griffin PR, Xu Y, Smith AG, Liu K, Calacay J, Feighner SD, Pong C, Leong D, Pomés A, Cheng K, Van der Ploeg LH, Howard AD, Schaeffer J, Leonard RJ

Biochemical and biophysical research communications1 Oct 2000Cited by 40 (Europe PMC)

PMID11027627 (opens in a new tab)DOI10.1006/bbrc.2000.3610 (opens in a new tab)PepBankPUB-11027627
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

1 result from studies that gave the peptide. No result from this study comes from people.

  1. 01LabIn vitro (cells)Mechanism

    In receptor assays, MK-0677 and adenosine produced GHS-R cross desensitization.

    In plain wordsIn lab tests, MK-0677 and adenosine caused receptor cross desensitization.

    Peptide
    MK-677 (ibutamoren)
    Outcome
    Not applicableCross desensitization
    Study

    n: not reported in source

    GHS-R-expressing cells
    Outcome group
    Receptor activity and mechanism · Pharmacology
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Cross desensitization of the GHS-R occurs with both MK-0677 and adenosine.

Studies that did not test the peptide alone1

In this study, MK-677 (ibutamoren) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking MK-677 (ibutamoren).

  1. 02LabNot a test of MK-677 (ibutamoren) aloneIn vitro (cell-free)Mechanism

    In ligand-binding and mutagenesis studies, the MK-0677 binding pocket differed from the adenosine binding site.

    In plain wordsIn lab tests, MK-0677 and adenosine bound to different receptor sites.

    Peptide
    MK-677 (ibutamoren)
    Outcome
    Not applicableLigand binding site
    Study

    n: not reported in source

    GHS-R-expressing cells
    Comparator
    Adenosine binding site
    Outcome group
    Receptor activity and mechanism · Pharmacology

    Source sentences

    Summary
    Ligand binding and site directed mutagenesis studies show that adenosine binds to a binding site that is distinct from the previously characterized MK-0677 and GHRP-6 binding pocket.

    In this study, MK-677 (ibutamoren) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking MK-677 (ibutamoren).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    14 Oct 2026, 05:02 UTC

    Study results updated

  2. Version 1

    14 Oct 2026, 01:46 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.